# AI Drug Discovery - Week of May 23–30, 2026

> Inaugural AI drug discovery podcast briefing for the week of May 23 to 30, 2026. A private CEO set the platform bar at 8 to 10 month med-chem cycles, RXRX and SDGR went quiet, and Lilly went on a $3.83B vaccine M&A spree.


## AI Drug Discovery: Week of May 23–30, 2026

### Subject: Private operators set the bar; public AI biotechs go quiet

---

```request-access
variant: ghost
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## TL;DR

- The loudest voice on AI drug discovery this week wasn't on a public earnings call, it was a private CEO claiming **8–10 month med-chem cycles** with **>100,000 compounds screened per week** and a strict no-outsourced-data policy. That bar will get cited at every RXRX and SDGR meeting.
- **RXRX and SDGR generated essentially zero substantive news flow** in the past seven days. RXRX closed +4.4% Friday to $3.59 (still ~50% off the 52-wk high); SDGR popped +7.3% to $15.20 on no fundamental catalyst. Quiet tape, twitchy multiples.
- **Lilly went on a $3.83B M&A spree**, three vaccine developers in one day, and posted clean VERVE-102 Phase 1 data. None of it was *AI-designed*, but it's the clearest read-through this week on how a Lilly-scale buyer thinks about platform M&A.

---

## What's new

**1. The platform-validation data point of the week came from a private CEO.** On [Citeline Podcasts (2026-05-29)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOg-2FM8nNMOB3GK8psZQU9UM3cQ0SNTgRbL14G1eM0LU-2F7M8JOzikQIHVFzGTTYPpWXk2NT-2BisMgcKMLeRp1TDnChvcpXUA-2BCieQuzbtswr3bMQ-3D-3D3u3Z_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUyxh-2FGzTrgOkjzrA1Y9gPVBywJlL-2Fx-2FO2lOP9CH6IGVVFyXnHIMYFthP3sr6gM22FJbhpQ1gPWB2wdLwU-2BHXHrRiX04FMhs-2BIbYY-2FOJHjVShg5gjQQf8g4guchTRJ-2FTumMKEfvmiLa04YxmCW-2BFpQG9dLuKxE-2B3Tpz4pfwMtRURw-3D-3D), Soley Therapeutics CEO Yeram Yegazarian, fresh off a **$200M Series C**, laid out specific platform mechanics that should make every public AI-biotech analyst recalibrate. Cycle time from screen to lead: **"8 to 10 months for some of our series of compounds,"** target-agnostic. Throughput: **>100,000 compounds per week** across **20–25 integrated instruments**. Data moat: **"we do not tap into any outsourced data,"** training foundation models on internally generated cellular imaging via NVIDIA B200 GPUs accessed through Oracle. Two Phase 1 INDs targeted by YE 2026 (AML and HNSCC), pre-IND meeting in 4–6 weeks. *Why it moves the thesis:* this is the kind of operator-stated benchmark that gets retrofit into the Schrödinger and Recursion pitch decks. If 8–10 months target-agnostic is the new normal at the private leaders, the question for SDGR and RXRX becomes whether their platforms can match it on equivalent compound classes, or whether they're being lapped by Series C names you can't yet buy.

**2. Pundit chatter put real numbers on the AI-biotech clinical funnel.** On [Limitless: An AI Podcast (2026-05-27)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOix0qEGQ1ZfETXryR8U6a1nUUDH9JpTJlFL4QpNnf-2BiVIaiX6fdr77Ee0wc1tz68vbBD-2F5CBC7NJDpk5wPcjxZBXiJoXVdK9IulxD56KfaJ-2Bw-3D-3DbRK6_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUyxh-2FGzTrgOkjzrA1Y9gPVBywJlL-2Fx-2FO2lOP9CH6IGVQXoZC-2B4V9zdQH-2FkL-2BxQw316ikroNyrHaM8TUvYMg4412gr7ep3TfpI06zng1pzVIVMN6ayDI-2B9BUySiIFl-2BYn8XdrumzJM1PLEXzwR4ZiB-2BfmgsZHGvr87rcECGqM7Y2g-3D-3D), the hosts cited **173 AI-discovered drug programs in clinical trials**, 94 Phase 1, 56 Phase 2, 15 Phase 3, and referenced a **$500M Lilly + a16z biotech fund** and a **~$2.1B Thrive-led round at Isomorphic Labs**. Treat these as directional, not gospel: the hosts are pundits, not operators, and named no source. But even at 50% accuracy the Ph1/Ph2/Ph3 split is striking, the field is no longer pre-clinical option value, it's a clinical-readout calendar. *Why it matters:* if 15 AI-discovered assets really are in Phase 3, the next 12–18 months will produce the first set of binary, real-world platform validation events, and "AI biotech" stops being a single asset class and starts being 173 separate risk profiles.

**3. Lilly bought three vaccine developers for up to $3.83B.** Per [WSJ (2026-05-26)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NrLSLX23ZACFhXg6TLo8iXEireH0OFSjH41P265klc7E2YsGsPTMyJHwlZUkwBHmtQtS2RfLSD2LF8PWHnFMYGbfkHiZwMvvWE4ZSYCHLPAtwJCV6x8JU-2Bcwps-2FgFD31jg-3D-3DzSf9_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUyxh-2FGzTrgOkjzrA1Y9gPVBywJlL-2Fx-2FO2lOP9CH6IGVbK3Lg6vkxgmIvnLjyXzOm0uxI7scguJNguwZd5WZ1lLa66wq6d5kQJLjarnurTfLtfajRkAL5VZxX-2FFkzIaWZYzlBiMHC0J-2BCS0TcWwir7U3BQfetVXfvefBbnt3-2B-2FZSg-3D-3D) and [MT Newswires (2026-05-26)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsdNR5hNcs1Jy8WmjXq-2F4EWdJgB-2F4UBVMTcN7rRzOWZKMst4uDHXg8fdJgoWc1hwUB1SEeL7KmyNaSUNDkm4e1fBFhvqiSxhNQqVPQovqgfdu-2BJx5WYOwfdkzBwGIZKTQdSG-2BwG1jsqls6vGHQH0rgUezWiDPh4y-2Fkro6AAmEoU-2FbnU7_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUyxh-2FGzTrgOkjzrA1Y9gPVBywJlL-2Fx-2FO2lOP9CH6IGVTKT2vb9T2eENUjZO7IukCO8EnVwFb6mX-2BODAJcs-2FmNc-2Fc2TOtvr9gDG7Cu0qhF0xBbbleDCKu-2FQVMCCxjEE6s8cyUtBQeFAyF3YlfLSF8JCUkseedOBr-2Bx6JPGSc6oSrw-3D-3D), LLY agreed to buy Curevo (up to $1.5B, shingles), LimmaTech (up to $780M, S. aureus), and Vaccine Company (up to $1.55B, EBV). CSO Dan Skovronsky: *"These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences."* None of these are AI-designed, but the pattern is what matters, Lilly has now done Kelonia (up to $7B), Centessa (up to $7.8B), Orna ($2.4B), and now $3.83B more. *Why it matters for our space:* Lilly is the single most active platform buyer in pharma. Every AI biotech CEO's BD slide ends with the implicit "and Lilly might buy us." Every $1B in deployed M&A capital is a data point on what Skovronsky values, and so far it's clinical-stage assets and **"differentiated technology platforms,"** not pure computational tools.

**4. VERVE-102 Phase 1 read out cleanly.** Per [MT Newswires (2026-05-26)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsdNR5hNcs1Jy8WmjXq-2F4EWdJgB-2F4UBVMTcN7rRzOWZKMst4uDHXg8fdJgoWc1hwUB1SEeL7KmyNaSUNDkm4e1fBFhvqiSxhNQqVPQovqgfdu-2BJx5WYOwfdkzBwGIZKTQdSG-2BwG1jsqls6vGHQH0rgUezWiDPh4y-2Fkro6AAmEoU-2FvCLR_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUyxh-2FGzTrgOkjzrA1Y9gPVBywJlL-2Fx-2FO2lOP9CH6IGVcdRpJ23-2FYfjNAp1Oa1-2B1rmUVwf3WaXvpWMnp8suxq7eAzbYNKRXwAqn-2F-2BjnLcWhEafSSyxibtvynVkxDeq520YLXoyaDSFPIF6CCGuyBf6j-2F527EOH5KtLAgUdE4wa1ng-3D-3D), Lilly's gene-editing therapy showed PCSK9 reductions of **51–88%** and LDL drops of **9–62%**, durable up to 18 months, with Phase 2 by YE 2026. Not AI-discovered, but a reminder: the bar for "platform credibility" is becoming clinical data, not screening throughput.

---

```request-access
variant: inline
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## The debate

**Bull steelman.** The cycle-time disclosures are no longer hand-wavy. Soley says 8–10 months target-agnostic on operator-recorded podcast tape. Limitless cites 173 programs in clinic. Lilly is writing $3.83B checks in a single day. If AI platforms genuinely compress hit-to-lead by 2–3x and shave even 200bps off Phase 1 attrition, the value math on SDGR's combined software+pipeline and RXRX's industrialized phenomics is dramatically under-priced at $1.1B and $1.6B market caps respectively. SDGR at 0.8x revenue with a Lilly-grade customer list, optionality on internal MALT1 / ATR / NLRP3, is functionally being valued as a stagnant CRO.

> If 8–10 months target-agnostic is the new normal at the private leaders, the question for SDGR and RXRX becomes whether their platforms can match it, or whether they're being lapped by Series C names you can't yet buy.

**Bear steelman.** Zero podcast-format coverage of RXRX, SDGR, Isomorphic, Insilico, Iambic from *insiders* in the past week is itself a tell. The narrative is being carried by private CEOs on niche shows and pundits on AI podcasts citing unverified figures. No AI-designed molecule has yet produced a pivotal-trial win. RXRX's $1.6B cap on $-1.16 trailing EPS and a 52-wk range of $2.77–$7.18 says the market priced in the Exscientia synergy story and then walked back. SDGR's software bookings need to inflect before the pipeline matters, and the week produced exactly no commercial color. Lilly's M&A choices reveal what the smartest buyer in pharma actually values, clinical-stage assets, and notably he's not buying SDGR. Partnerships are option value; cash burn is real; the platform premium dies on the first underpowered Phase 2.

**Where I net out.** This was a week to listen, not act. The single most useful new data point is Soley's cycle-time number: bring it to your next RXRX and SDGR call and ask management to benchmark against it. The next platform-validation pivot will come from clinical data, not earnings.

---

## Stocks in play

**RXRX, Recursion Pharmaceuticals ($3.59, +4.4% Friday, mkt cap $1.6B, 52-wk $2.77–$7.18).**
- *Bull:* Industrialized phenomics + Exscientia chem stack + Sanofi/Bayer/Roche option pool. Stock down ~50% off the high with the worst news (Exscientia integration noise) priced in.
- *Bear:* No operator commentary on platform progress this week. Cash burn vs cash runway is the gating variable; $-1.16 trailing EPS with no near-term commercial revenue. Multiple still requires belief.
- *Next catalyst:* Any first-of-platform IND filing or partnered Phase 1 readout. Cash runway disclosure on next Q call.

**SDGR, Schrödinger ($15.20, +7.3% Friday, mkt cap $1.1B, 52-wk $10.95–$27.63).**
- *Bull:* The closest thing to a SaaS book in AI drug discovery: physics-based simulation moat, LiveDesign customer stickiness, internal MALT1/ATR/NLRP3 optionality. At ~$1.1B cap the pipeline is being given away free.
- *Bear:* Zero substantive news this week. Software ACV growth needs to reaccelerate; pipeline assets are years from value-inflecting data.
- *Next catalyst:* Next quarterly software bookings/ACV print. Any internal-program clinical update.

**LLY, Eli Lilly ($1,105.44, -1.9% Friday, mkt cap $1.04T, P/E 39.2x, 52-wk $623.78–$1,149.10).**
- *Bull:* Confirmed appetite to deploy double-digit billions on platforms and clinical-stage assets. AI/ML BD funnel via TuneLab and Isomorphic-style external partnerships. GLP-1 cash engine intact.
- *Bear:* The street's $1,247.64 mean target implies less than 15% upside; multiple is rich, comparable to consumer staples in 2017.
- *Next catalyst:* VERVE-102 Phase 2 start by YE 2026. Any AI-discovery partnership disclosure with disclosed economics.

---

```request-access
variant: inline
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## Read-throughs

- **Big-pharma partners.** Lilly's $3.83B vaccine spree ([WSJ](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NrLSLX23ZACFhXg6TLo8iXEireH0OFSjH41P265klc7E2YsGsPTMyJHwlZUkwBHmtQtS2RfLSD2LF8PWHnFMYGbfkHiZwMvvWE4ZSYCHLPAtwJCV6x8JU-2Bcwps-2FgFD31jg-3D-3DOkTp_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUyxh-2FGzTrgOkjzrA1Y9gPVBywJlL-2Fx-2FO2lOP9CH6IGVUZg71L4H8kk4c73xBzGObyTbakd16bIwuB1ybwigGC9xKgHKRGH12ZvDlxQ95K5ag5KKOSPqgJEC-2BaYQZgxpzNNcrv4MK6eYoby2b2foY0N-2B7SKChTkIEexon-2BIsYL69g-3D-3D)) is the template. AI biotechs that *aren't* generating clinical data should expect to be courted as partners, not acquirers' targets. The deal premium goes to the platforms with assets, not the toolmakers.
- **CRO/CDMO and lab automation.** Soley's disclosure of **20–25 instruments in an integrated stack** is the kind of footprint that ends up running through Danaher, Thermo, Sartorius, and Tecan order books. The wet-lab integration cap-ex story is alive and quantifiable ([Citeline](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOg-2FM8nNMOB3GK8psZQU9UM3cQ0SNTgRbL14G1eM0LU-2F7M8JOzikQIHVFzGTTYPpWXk2NT-2BisMgcKMLeRp1TDnChvcpXUA-2BCieQuzbtswr3bMQ-3D-3Dy_Gw_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUyxh-2FGzTrgOkjzrA1Y9gPVBywJlL-2Fx-2FO2lOP9CH6IGVRDliWG5KpUraf4zC2w3Rc2YyK3MBAurpmrYjLp9ObxgIfQgPtFIw6DYyeWgnEUDs2Slvv5wWsd74MWoc-2Fm-2Fai9VTMvNidHuStZR59SZSWcPDWlTCuWn0QuQVzFFTXlp7w-3D-3D)).
- **Compute and cloud.** Soley naming **NVIDIA B200 GPUs accessed through Oracle** ([Citeline](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOg-2FM8nNMOB3GK8psZQU9UM3cQ0SNTgRbL14G1eM0LU-2F7M8JOzikQIHVFzGTTYPpWXk2NT-2BisMgcKMLeRp1TDnChvcpXUA-2BCieQuzbtswr3bMQ-3D-3DP24g_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUyxh-2FGzTrgOkjzrA1Y9gPVBywJlL-2Fx-2FO2lOP9CH6IGVTzuyI94u5mG-2Bw7oNaYhxobsKIe3VOHuABZLtSvh8G4qIxcRdz8pmlZAg5CXMFpk4tK2ChXwQ43dkcYfk92LV18mPfJoNGfep-2FEV6wf2VX-2Bm4M-2BBlntjl2Q1PNU5bpCV1g-3D-3D)) is one of the cleanest public attributions yet of biotech compute to a hyperscaler. Watch ORCL's life-sciences vertical commentary on the next call. Note: this is a single private-company anchor, not a sector signal.
- **Private benchmarks.** Isomorphic ($2.1B raise per pundit cite, [Limitless AI](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOix0qEGQ1ZfETXryR8U6a1nUUDH9JpTJlFL4QpNnf-2BiVIaiX6fdr77Ee0wc1tz68vbBD-2F5CBC7NJDpk5wPcjxZBXiJoXVdK9IulxD56KfaJ-2Bw-3D-3D91hX_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUyxh-2FGzTrgOkjzrA1Y9gPVBywJlL-2Fx-2FO2lOP9CH6IGVVbX15AxDPgNdSLkc4JwRKI75Ak7MrU8PbwYENx81KJg5Nz-2BV8aY9pAbEsy4jYHMKCR-2BtX-2FWaUKdOWFzIYNyFaG1-2FtjEaoTvgXjmiXxbNr5uTslgPIhUmnzzkA0axDQWSQ-3D-3D), verify before quoting), Insilico, Iambic, Genesis, Generate, every $1B raised privately is a year SDGR and RXRX have to compete for talent and compute without dilution.

---

## What changed vs last week

This is the inaugural issue, so the answer is "everything." But the structural observation worth flagging: **operator/insider podcast coverage of public AI biotechs (RXRX, SDGR, LLY's AI deals, Isomorphic) was zero in the past 7 days.** That's a notable silence into the summer conference circuit. We'll be watching whether it persists or breaks at BIO 2026 (June).

---

## Sources

- [Citeline Podcasts, Decoding Cell Stress at Soley Therapeutics, 2026-05-29](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOg-2FM8nNMOB3GK8psZQU9UM3cQ0SNTgRbL14G1eM0LU-2F7M8JOzikQIHVFzGTTYPpWXk2NT-2BisMgcKMLeRp1TDnChvcpXUA-2BCieQuzbtswr3bMQ-3D-3DYbSb_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUyxh-2FGzTrgOkjzrA1Y9gPVBywJlL-2Fx-2FO2lOP9CH6IGVb5cWz-2BXbcNuxR9NZRj3gneJbFBGGeCH7hrMDmXsb75atPTJodVGIMPPrI7TuzWpAAbf5RewMyDKWe2pguI7g-2FJB2ETEf3i-2FWnhoAo1sDavRXMGdf6j5prAHuTnKWjykfA-3D-3D), Yeram Yegazarian (CEO, Soley Therapeutics) [OPERATOR]
- [Limitless: An AI Podcast, Encouraging Athletes to Take Steroids: Bryan Johnson's Enhanced Games, 2026-05-27](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOix0qEGQ1ZfETXryR8U6a1nUUDH9JpTJlFL4QpNnf-2BiVIaiX6fdr77Ee0wc1tz68vbBD-2F5CBC7NJDpk5wPcjxZBXiJoXVdK9IulxD56KfaJ-2Bw-3D-3DAxBj_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUyxh-2FGzTrgOkjzrA1Y9gPVBywJlL-2Fx-2FO2lOP9CH6IGVQuEBnRowEVzBzCB1ydkjpVoj5GbDSid6auWmJEg7G2iFT-2BfpTDq1d7GGhicS5CHoN-2BvSwVKvNqb8cuzT0W2aO67XBk9PzWz6vL4GbFpr00eDK-2B6eDMpTSU5-2F7EJjvbktg-3D-3D), Josh / Ejaz (co-hosts) [PUNDIT, unverified figures, treat directionally]
- [WSJ, Lilly Agrees to Buy Trio of Vaccine Developers, 2026-05-26](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NrLSLX23ZACFhXg6TLo8iXEireH0OFSjH41P265klc7E2YsGsPTMyJHwlZUkwBHmtQtS2RfLSD2LF8PWHnFMYGbfkHiZwMvvWE4ZSYCHLPAtwJCV6x8JU-2Bcwps-2FgFD31jg-3D-3Deqmt_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUyxh-2FGzTrgOkjzrA1Y9gPVBywJlL-2Fx-2FO2lOP9CH6IGVaikJlH-2FYAh0U6N0tFO7t99G36ZK7Bln1LeyUKiUnAuYUz8MZD3DaL8E0s0Gcfd2JCqDHUNrgPajOj-2Fi-2BesGqy-2Fp6e-2F3-2FbTP81DcTrk0UariZ4-2B-2FYBBOnnzoZayP7uOazA-3D-3D)
- [MT Newswires via TheFly, Lilly $3.83B vaccine acquisitions and VERVE-102 Phase 1 data, 2026-05-26](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsdNR5hNcs1Jy8WmjXq-2F4EWdJgB-2F4UBVMTcN7rRzOWZKMst4uDHXg8fdJgoWc1hwUB1SEeL7KmyNaSUNDkm4e1fBFhvqiSxhNQqVPQovqgfdu-2BJx5WYOwfdkzBwGIZKTQdSG-2BwG1jsqls6vGHQH0rgUezWiDPh4y-2Fkro6AAmEoU-2FQlGc_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUyxh-2FGzTrgOkjzrA1Y9gPVBywJlL-2Fx-2FO2lOP9CH6IGVe4L-2B29nDGKeeHTu3EOMWUvJKBAnmUFwoJ-2FcpSl85D4teF3utkAE-2B7koEGYogcf8A6JrVidN4gA7orCqsunHqsnWGRCYBH-2B-2Bgp2b0r8qtEV7rJBl0w0s0ADhHAr5eoZu5g-3D-3D)

```request-access
variant: banner
heading: Run your own corpus.
description: matterfact is deployed with select institutional partners. Request access to run it on your own coverage.
buttonText: Request access
```